1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Medical Research is sponsored by Robert J.
Kleberg, Jr. and Helen C. Kleberg Foundation. The Foundation seeks highly innovative and groundbreaking medical research proposals from top-tier institutions in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health.
Get alerted about grants like this
Save a search for “Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Medical Research - Robert J. Kleberg, Jr. and Helen C. Kleberg FoundationRobert J.
Kleberg, Jr. and Helen C. Kleberg Foundation The Foundation is seeking highly innovative and groundbreaking medical research proposals from top tier institutions in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. Proposals should be distinctive and novel in their approaches, question the prevailing paradigm, and lead to advancement of knowledge in the field.
A highly qualified scientific advisory committee will review all proposals. Applications are highly competitive. Priority is given to organizations with whom the Foundation has had a long-standing relationship, preferably in Texas.
All applications must be approved by the University Provost or the Vice President of Research, and should be submitted through the office of sponsored research or like office that provides institutional approval for the request. Studies selected through an internal competition are preferred. Applications submitted by an individual researcher will NOT be considered.
Medical research institutions may submit one application each grant cycle, regardless if they have an open grant, and regardless of the number of affiliated entities within the institution. The medical research study application has a format similar to that of NIH. There is a separate application called Medical Research-Other that should be used for medical research-related requests other than medical research studies.
This application is restricted and requires an access code. Please contact Foundation staff at margretb@alexventures. com or call Margret at 210-316-8398 before you set up a new account in the online system, begin a Medical Research Study Pre-Request , if you have any questions, i f you are unsure which application to use or whether you are eligible to apply, or to obtain the access code.
Please review the grant guidelines and the PDF documents below to be sure to submit a complete application: Application Content and Attachments – Medical Research Medical Research Study Application – List of Questions Online Application Instructions 2025 Medical Research Awards Baylor College of Medicine, Houston, TX S.
Boeynaems – Toxic Positivity: Antimicrobial peptides driving maladaptive neuroinflammation – 3 Years Johns Hopkins University, Baltimore, MD S. Watanabe – Continuation: A potential novel bioactive molecule in neurodegeneration – 2 Years Mayo Clinic, Rochester, MN A. Revzin – Novel mass spectrometry analysis of cancer biomarkers on extracellular vesicles – 3 Years Memorial Sloan Kettering Cancer Center, New York, NY B.
Greenbaum – Structure-guided TCR specification and design for precision immunotherapy – 3 Years Rice University, Houston, TX R. Richards-Kortum – Access BreastDX to Expand Breast Cancer Diagnosis – 3 Years Stanford University, Stanford, CA J. Wu – Engineering Human Heart Models for Cardiovascular “Clinical Trials in-a-Dish” – 3 Years Texas A&M Foundation, College Station, TX K.
Hobbs – Immediate and Sustained Methods for Protecting the Vasculature After Snake Bite – 1 Year University of California, San Francisco, CA J. Reiter – Cilia as Cancer’s Achilles’ Heel: New Therapeutic Strategies for Medulloblastoma – 3 Years Washington University, St. Louis, MO M.
Chheda – IND-enabling studies and a first in human trial of Zika virus in brain cancer – 3 Years 2024 Medical Research Awards Baylor College of Medicine, Houston, TX A. Maresso – Phage Therapy Induced Vaccination Against Pandemic Drug-Resistant Bacteria – 3 Years S. Gunter – A Citizen Science Approach to Collect Ticks as Proof-of-Concept – 2 Years J.
David Gladstone Institutes, San Francisco, CA L. Shipman – Engineering Approaches to Phage Therapy – 3 Years Johns Hopkins University, Baltimore, MD Inoue/Leung – Shattering the Paradigm of Translation Regulation for Health and Diseases – 3 Years Massachusetts Eye and Ear, Boston, MA J. Arboleda-Velasquez – Antibody Targeting APOE Interactions for Alsheimer’s – 2 Years Rice University, Houston, TX H.
Xiao – Overcoming the Blood-Brain Barrier in Effective Treatments for Brain Metastasis – 3 Years Thomas Jefferson University, Philadelphia, PA K. Bussard – Reducing Osteolytic Bone Destruction in Bone Metastatic Breast Cancer – 3 Years University of California, San Francisco, CA D. Fujimori – A Chemical Biology Approach to Stimulate Antitumor Immunity – 3 Years University of Pennsylvania, Philadelphia, PA S.
Berger – Epigenetic Dysfunction Drives Alzheimer’s Disease – 3 Years University of Texas at Austin, TX A. Ellington – Microbial Delivery of mRNA Vaccines and Therapeutics – 2 Years Vanderbilt University Medical Center, Nashville, TN B. Park – Overcoming Immune Exclusion in Microsatellite Stable Colon Cancer – 3 Years 2023 Medical Research Awards Baylor College of Medicine, Houston, TX S.
E. Crawford – Using Novel Tools to Achieve a Hepatitis B Virus Functional Cures – 3 Years S. Gunter – A citizen science approach to collect adequate ticks as proof-of-concept – 1 Year Boston Children’s Hospital, Boston, MA M.
Moses – A dual targeted theranostic approach to the treatment of pancreatic cancer – 3 Years Fred Hutchinson Cancer Research Center, Seattle, WA K. Cheung – Interrogating intercellular signaling in triple-negative breast cancer – 3 Years Texas A&M Foundation, College Station, TX J. Hyde – Early Lyme Disease Diagnostic to Detect Viable B.
burgdorferi – 3 Years Thomas Jefferson University, Philadelphia, PA A. Snook – Universal Cell Therapy for Cancer – 3 Years University of California, San Francisco, CA B. Javid – A generalized strategy for bacterial antivirulence therapy – 3 Years University of Texas at Austin, TX D.
Ghosh – mRNA delivery of intrabodies against the intracellular targets of cancer – 3 Years University of Texas MD Anderson Cancer Center, The, Houston, TX J. Hu – Tackling cancer therapy-induced central nervous system deficits – 3 Years University of Texas Rio Grande Valley, McAllen, TX Luminary Scholars Program – 4 Years UT Southwestern Medical Center, Dallas, TX D.
Greenberg – Antisense Antibiotics for Drug-Resistant Pseudomonas aeruginosa – 3 Years J. Herz – Restoring Endolysosomal pH Homeostasis to Prevent Alzheimer’s Disease – 3 Years Vanderbilt University Medical Center, Nashville, TN B. Park – Blocking the evolution of drug resistance in cancer – 3 Years 2022 Medical Research Awards Fred Hutchinson Cancer Research Center, Seattle, WA J.
Lee – Disrupting ERAP activity to advance immunotherapy in prostate cancer – 3 Years Johns Hopkins University, Baltimore, MD S. Watanabe – A potential novel bioactive molecule in neurodegeneration – 1 Year Monell Chemical Senses Center, Philadelphia, PA B. Kimball – Classification of Febrile Disease via Detection of Urinary or Saliva Volatiles – 1 Year Rice University, Houston, TX J.
Chappell – Smart RNA antibiotics: trojan horse drugs selective for pathogenic microbes – 3 Years Stanford University, Stanford, CA C. Curtis – Measuring the repeatability of clonal evolution and defining its contingencies – 3 Years University of California, San Francisco, CA K. Shokat – A chemical-genetic approach to elucidate healthspan regulation – 3 Years J.
Bondy-Denomy – Factors that antagonize bacteriophage infection in a human pathogen – 3 Years University of Texas at Austin D. Taylor – Structure-based design of next-generation versatile, high-fidelity Cas9 variants – 3 Years University of Texas Health San Antonio D. Halff – Transplantation Matching Decisions: Surgeon-AI Collaborative Platform – 3 Years 2021 Medical Research Awards Baylor College of Medicine, Houston, TX A.
Maresso – Designer Medicines for Evolving Pathogens – 3 Years P. Hotez – Chagas Disease Vaccine Combining RNA and Protein Technologies – 1 Year Boston Children’s Hospital, Boston, MA L. Zon – Strategies for Bone Marrow Inflammation in Clonal Hematopoiesis and Leukemia – 3 Years Massachusetts Eye and Ear, Boston, MA J.
Arboleda-Velasquez – Antibody Targeting APOE Interactions with Glycosaminoglycans – 3 Years Memorial Sloan Kettering Cancer Center, New York, NY G. Diehl – Developmental Regulation of Microbiota Specific Inflammatory T Cells – 3 Years Rice University, Houston, TX G. Bao – A Generalizable Platform for In Vivo Genome Editing – 3 Years Stanford University, Stanford, CA M.
Wernig – Towards Next Generation Brain Cell Therapies- 3 Years The University of Texas Medical Branch, Galveston, TX Pei-Yong Shi – Development of an Engineered Zika Virus for Glioblastoma Therapy – 2 Years The University of Texas Rio Grande Valley, McAllen, TX Obstetrics & Gynecology Residency Program in the Mid-Rio Grande Valley – 3 Years Vanderbilt University Medical Center, Nashville, TN Pietenpol and Cortez – Defining a New Pathway to Treat MYC-Driven Cancers – 3 Years 2020 Medical Research Awards Baylor College of Medicine, Houston, TX P.
Hotez – Advancing an RBD-based Vaccine Against COVID-19 – 1 Year Fred Hutchinson Cancer Research Center, Seattle, WA A. Hsieh – Protein Synthesis Dynamics in Advanced Bladder Cancer – 3 Years Memorial Sloan Kettering Cancer Center, New York, NY C. Rudin – Using new tools to deeply interrogate drivers of lung cancer metastasis – 3 Years Monell Chemical Senses Center, Philadelphia, PA B.
Kimball – Classification of Febrile Disease via Detection of Urinary or Saliva Volatiles – 2 Years Rice University, Houston, TX J. Miller – A throughput system to test antiviral compounds against virus-infected mosquitoes – 3 Years Stanford University, Stanford, CA H.
Nakauchi – Redefining mammalian pluripotent stem cell states – 3 Years Texas Bomedical Research Institute, San Antonio, TX Recruitment of Virologist Dr. Martinez-Sobrido – 4 Years University of Pennsylvania, Philadelphia, PA S. Berger – Epigenetic Dysfunction Drives Alzheimer’s Disease – 3 Years University of Texas at San Antonio, San Antonio, TX J. Hsieh – A Personalized Approach to Alzheimer’s Disease in Hispanic Families – 3 Years G.
Perry – Amyloidß Protective Hypothesis: A Cure for Alzheimer’s Disease – 3 Years University of Texas MD Anderson Cancer Center, The, Houston, TX P. Sharma – Improving anti-tumor responses to immunotherapy using ARID1A + CXCL13 – 3 Years The Kleberg Innovator/Investigator Award – 3 Years UT Southwestern Medical Center, Dallas, TX E.
Maher – Matching IDH Driver Status to Treatment Timing in Glioma – 1 Year 2019 Medical Research Awards Monell Chemical Senses Center, Philadelphia, PA Dr. Preti – Effective Ovarian Cancer Screening Diagnostic Stanford University, Stanford, CA Dr. Weissman – Profiling Immune Responses to Lyme Disease and How They Impact Treatment Efficacy Dr. Monje – Targeting Ion Channel Physiology in Malignant Glioma Through Neurological Drug Repurposing University of Pennsylvania, Philadelphia, PA Dr. Brinster – Altering the Genes of Farm Animals University of California, San Francisco, CA Dr. McManus – Evolving CRISPR Therapies University of Texas Medical Branch, Galveston, TX Dr. Shi – A Universal Vaccine Platform 2018 Medical Research Awards Johns Hopkins University, Baltimore, MD Targeting Mitophagy as a New Strategy to Treat Non-Alcoholic Steatohepatitis Texas A&M Foundation, College Station, TX Innovative Technologies to Minimize the Risk for the Re-Emergence of Bovine Babesiosis in the U.S. (Includes Contingency Award for Years 2 and 3) University of California, San Francisco, CA Early Detection and Removal of High-Risk Pre-Cancer, Cancer and Metastatic Lesions Using Engineered University of Pennsylvania, Philadelphia, PA Epigenetic Dysfunction in Human Alzheimer’s Disease University of Texas, Austin, TX Improving the Efficiency and Specificity of Cas9 Enzymes 2017 Medical Research Awards Baylor College of Medicine, Houston, TX Impact of Microbiota Driven T Cell Selection on Inflammatory Disease Fred Hutchinson Cancer Research Center, Seattle, WA Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells for Single Cord Blood Transplant in Patients with Hematologic Malignancies Houston Methodist Hospital Foundation, Houston, TX New Mechanisms and Strategies in Prevention of Transplant Rejection A New Biomimetic Approach in the Treatment of Cardiovascular Inflammation Memorial Hermann Foundation, Houston, TX Plasma Exchange to Treat Alzheimer’s Disease Memorial Sloan Kettering Cancer Center, New York, NY Mechanistic Analyses of Pancreatic Cancer Evolution Rice University, Houston, TX Design and Fabrication of Interpenetrating Vascular Networks in Lung Tissue Mimics Texas A&M Foundation, College Station, TX Transformative and Affordable Medical Technologies and Systems to Improve Diabetes Health Texas Children’s Hospital, Houston, TX Network Systems Biology to Identify and Test Novel Multivalent mRNA Lipopolyplex Vaccines Texas Heart Institute, Houston, TX Targeting the Cardiovascular Inflammatory Receptor to Enhance Stem Cell Transplantation in Cancer University of Houston, Houston, TX Gravin Signalosome: A Novel Therapeutic Drug Target for the Treatment of Heart Failure University of Texas at Austin, Austin, TX A Personalized Approach to T Cell Receptor Re-Directed Adoptive Cell Transfer Therapy in Cancer University of Texas at San Antonio, San Antonio, TX Accelerating Research in Brain Health University of Texas Medical Branch, Galveston, TX A Rapid Zika Diagnostic Assay for Patients Innovative Methods to Disrupt Acquisition and Transmission of Viruses by Mosquitoes and Ticks UT Southwestern Medical Center, Dallas, TX Matching IDH Driver Status toTreatment Timing in Glioma Vanderbilt University Medical Center, Nashville, TN Accelerating the Transition from Discovery to Clinical Implementation in Precision Medicine Washington University, St.
Louis, MO Using Zika Virus to Treat Glioblastoma
According to the current listing, eligibility includes: Medical research institutions (universities are eligible) may submit one application each grant cycle, approved by the University Provost or Vice President of Research. Confirm the full requirements in the official notice before applying.
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Medical Research is funded by Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.